VERIFIEDET Finance·28 Sept 2026neutral

Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9

AI Summary

·Sun Pharma has entered into an exclusive agreement with LIB Therapeutics for the cholesterol-lowering drug Lerodalcibep.
·The agreement grants Sun Pharma rights to Lerodalcibep in all global markets except the United States and China.
·Lerodalcibep is a PCSK9 inhibitor administered once monthly and will be marketed as Lyrokaul in Europe.